Valeant Pharmaceuticals (VRX) PT Lowered to $35 at Stifel, Keeps 'Buy' as Company Moves Beyond 'Stabilization Phase'
Tweet Send to a Friend
Stifel lowered its price target on Valeant Pharmaceuticals (NYSE: VRX) to $35.00 (from $45.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
